Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.

@article{Goldstein2008ConcurrentDP,
  title={Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.},
  author={Lori J. Goldstein and Anne O'Neill and Joseph A Sparano and Edith A. Perez and Lawrence N. Shulman and Silvana Martino and Nancy E. Davidson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 25},
  pages={4092-9}
}
PURPOSE The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant regimen. Doxorubicin and docetaxel (AT) is one of the most active cytotoxic regimens for metastatic breast cancer. The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer. PATIENTS AND METHODS Women with invasive breast cancer were eligible if there were one to three positive lymph nodes or if the node-negative tumor was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 1 Excerpt

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006
View 2 Excerpts

Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006

Adjuvant docetaxel for node-positive breast cancer.

The New England journal of medicine • 2005
View 2 Excerpts

Similar Papers

Loading similar papers…